Why the Lone EpiPen Competitor Hasn’t Taken Off

Tuesday, November 1, 2016 - 23:31 in Mathematics & Economics

Adrenaclick, a cheaper alternative, has benefited from furor over EpiPen pricing. But its maker is struggling to meet demand, and a generic EpiPen is near.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net